BreathID 13C-Methacetin Breath Test for Detecting Cirrhosis

Completed · Phase 3

Conditions studied: Chronic Liver Disease

In brief

This trial is a pivotal trial to validate the use of a 13 C labeled substrate called methacetin and the BreathID automatic breath testing system, for determination of cirrhosis in patients with chronic liver disease.

Key facts

Study ID
NCT00736840
Run by
Meridian Bioscience, Inc.
People needed
414
Starts
2008-08-01
Expected to finish
2009-09-01
Last updated by the study team
2023-01-12

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.